Gilead Sciences, Inc.
GILD Healthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.
Follow GILD
Gilead Sciences, Inc. (GILD) EV/FCF
As of 9 October 2026, Gilead Sciences, Inc. (GILD) trades at a EV/FCF of 16.3×. Over the past ten years it has ranged from 5.9× (December 2016) to 22.3× (February 2026); the current reading is higher than 89% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 18.0× | 40.45% |
| FY2024 | 12.8× | (22.70%) |
| FY2023 | 16.6× | 8.63% |
| FY2022 | 15.2× | 46.60% |
| FY2021 | 10.4× | (20.59%) |
| FY2020 | 13.1× | 30.03% |
| FY2019 | 10.1× | (5.26%) |
| FY2018 | 10.6× | 13.99% |
| FY2017 | 9.3× | 32.44% |
| FY2016 | 7.0× | (7.46%) |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | 13.9× | (24.13%) |
| Mar 2026 | 18.3× | 2.02% |
| Dec 2025 | 18.0× | 5.88% |
| Sep 2025 | 17.0× | 0.83% |
| 42 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| SNY Sanofi compare | 7.8× |
| BMY Bristol Myers Squibb Company compare | 13.4× |
| GILD Gilead Sciences, Inc. | 16.3× |
| NVS Novartis AG compare | 20.6× |
| PFE Pfizer Inc. compare | 20.9× |
| NVO Novo Nordisk A/S compare | 24.4× |
| MRK Merck & Co., Inc. compare | 25.1× |
| AMGN Amgen Inc. compare | 27.4× |
| AZN AstraZeneca PLC compare | 43.3× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on GILD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement